BR0210707A - Formulações de olopatadina para administração tópica - Google Patents

Formulações de olopatadina para administração tópica

Info

Publication number
BR0210707A
BR0210707A BR0210707-4A BR0210707A BR0210707A BR 0210707 A BR0210707 A BR 0210707A BR 0210707 A BR0210707 A BR 0210707A BR 0210707 A BR0210707 A BR 0210707A
Authority
BR
Brazil
Prior art keywords
formulations
olopatadine
topical administration
olopatadine formulations
topical
Prior art date
Application number
BR0210707-4A
Other languages
English (en)
Other versions
BRPI0210707B8 (pt
BRPI0210707B1 (pt
Inventor
Ernesto J Castillo
Wesley Wehsin Han
Huixiang Zhang
Haresh G Bhagat
Onkar N Singh
Joseph Paul Bullock
Suresh C Dixit
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23162841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0210707(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of BR0210707A publication Critical patent/BR0210707A/pt
Publication of BRPI0210707B1 publication Critical patent/BRPI0210707B1/pt
Publication of BRPI0210707B8 publication Critical patent/BRPI0210707B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FORMULAçõES DE OLOPATADINA PARA ADMINISTRAçãO TóPICA". A presente invenção refere-se a formulações tópicas de olopatadina para tratamento de distúrbios alérgicos ou inflamatórios do olho e nariz. As formulações aquosas contêm aproximadamente 0,17 - 0,62% (peso/volume) de olopatadina e uma quantidade de polivinilpirrolidona, ou ácido poliestireno sulfónico, suficiente para melhorar a estabilidade física das formulações.
BRPI0210707A 2001-06-27 2002-06-19 composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação BRPI0210707B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30131501P 2001-06-27 2001-06-27
PCT/US2002/019417 WO2003002093A1 (en) 2001-06-27 2002-06-19 Olopatadine formulations for topical administration

Publications (3)

Publication Number Publication Date
BR0210707A true BR0210707A (pt) 2004-07-20
BRPI0210707B1 BRPI0210707B1 (pt) 2015-08-04
BRPI0210707B8 BRPI0210707B8 (pt) 2021-05-25

Family

ID=23162841

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210707A BRPI0210707B8 (pt) 2001-06-27 2002-06-19 composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação

Country Status (21)

Country Link
US (2) US6995186B2 (pt)
EP (1) EP1399127B1 (pt)
JP (5) JP4827374B2 (pt)
KR (1) KR100884711B1 (pt)
CN (1) CN1211125C (pt)
AR (1) AR034619A1 (pt)
AT (1) ATE295149T1 (pt)
AU (1) AU2002310461B2 (pt)
BR (1) BRPI0210707B8 (pt)
CA (1) CA2447924C (pt)
DE (1) DE60204142T2 (pt)
DK (1) DK1399127T3 (pt)
ES (1) ES2238574T3 (pt)
GC (1) GC0000397A (pt)
HK (1) HK1059573A1 (pt)
MX (1) MXPA03011947A (pt)
PL (1) PL205565B1 (pt)
PT (1) PT1399127E (pt)
TW (1) TWI231759B (pt)
WO (1) WO2003002093A1 (pt)
ZA (1) ZA200308771B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
KR101252863B1 (ko) * 2004-04-08 2013-04-09 교와 핫꼬 기린 가부시키가이샤 안정성이 향상된 고형 제제 및 그 제조 방법
KR20070001232A (ko) * 2004-04-21 2007-01-03 교와 핫꼬 고교 가부시끼가이샤 만성 부비강염의 예방 및/또는 치료제
WO2006004757A2 (en) * 2004-06-28 2006-01-12 Alcon, Inc. Topical formulations for treating allergic diseases
DE602005016833D1 (de) * 2004-11-24 2009-11-05 Alcon Inc Verfahren zur Verabreichung eines Nasensprays
WO2006097458A1 (en) * 2005-03-15 2006-09-21 Nycomed Gmbh Novel combination
EP1901708B1 (en) 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CN101553206B (zh) * 2006-11-09 2012-11-21 爱尔康研究有限公司 用于药物递送的水不溶性聚合物基质
US20080114076A1 (en) * 2006-11-09 2008-05-15 Alcon Manufacturing Ltd. Punctal plug comprising a water-insoluble polymeric matrix
JP5323720B2 (ja) * 2006-12-18 2013-10-23 アルコン リサーチ， リミテッド 眼用薬物送達のためのデバイスおよび方法
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine
BRPI0721255B8 (pt) * 2007-02-07 2021-05-25 Alcon Pharmaceuticals Ltd composições de olopatadina para administração nasal tópica
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
CA2682730A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnf.alpha. plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20100227917A1 (en) * 2007-09-06 2010-09-09 Masashi Nakakura EYE DROP CONTAINING DIBENZ[b,e]OXEPIN DERIVATIVE
CN102026665A (zh) * 2008-05-19 2011-04-20 爱尔康研究有限公司 含有羧基乙烯基聚合物和聚维酮聚合物的药物组合物
WO2010027539A1 (en) * 2008-08-26 2010-03-11 Trutek Corp. Electrostatically charged mask filter products and method for increased filtration efficiency
JP2012509250A (ja) * 2008-08-28 2012-04-19 トルテック コーポレーション 抗ヒスタミン及び抗ヒスタミン様経鼻適用製品及び方法
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
WO2011008923A2 (en) * 2009-07-17 2011-01-20 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
WO2011027322A1 (en) * 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
WO2011038066A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists
JP5893561B2 (ja) 2009-09-25 2016-03-23 シャイア・オーファン・セラピーズ・ゲーエムベーハーＳｈｉｒｅ Ｏｒｐｈａｎ Ｔｈｅｒａｐｉｅｓ ＧｍｂＨ 新規ｎｐｒ−ｂアゴニスト
RU2012117141A (ru) * 2009-10-01 2013-11-10 Алькон Рисерч, Лтд. Композиции олопатадина и способы их применения
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
CA2805656A1 (en) * 2010-07-21 2012-01-26 Alcon Research, Ltd. Pharmaceutical composition with enhanced solubility characteristics
WO2012063237A2 (en) * 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN102885767A (zh) * 2012-11-02 2013-01-23 江苏吉贝尔药业有限公司 一种新的盐酸奥洛他定滴眼液及其制备方法
JP2020505476A (ja) 2017-02-01 2020-02-20 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 眼科障害の治療のための化合物および組成物
WO2018235935A1 (ja) * 2017-06-23 2018-12-27 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
JP7037349B2 (ja) * 2017-06-23 2022-03-16 参天製薬株式会社 水溶性粘稠化剤を含有する医薬組成物
US20230018472A1 (en) * 2019-12-06 2023-01-19 Toko Yakuhin Kogyo Co., Ltd. Rhinenchysis composition containing olopatadine
CN111700860A (zh) * 2020-07-09 2020-09-25 浙江尖峰药业有限公司 盐酸奥洛他定滴眼液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
ES2053678T3 (es) * 1987-11-13 1994-08-01 Asta Medica Ag Procedimiento para preparar un medicamento con contenido de azelastina para la aplicacion nasal y/u ocular.
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
JP3662944B2 (ja) 1993-08-24 2005-06-22 協和醗酵工業株式会社 点鼻剤
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US5641805A (en) 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
AU7833698A (en) * 1997-06-09 1998-12-30 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
BR9906772A (pt) 1998-07-14 2000-09-26 Alcon Lab Inc Uso de ácido 11-(3-dimetilamino-propilideno)-6,11diidrodibenz[b,e]o xepin-2-acético para a fabricação de um medicamento para tratamento de desordens inflamatórias oftálmicas não-alérgicas e para prevenção de neovascularização ocular
US6146622A (en) * 1998-10-27 2000-11-14 Alcon Laboratories, Inc. Use of certain anionic amino acid based surfactants to enhance antimicrobial effectiveness of topically administrable pharmaceutical compositions
PT1124535E (pt) * 1998-10-27 2003-04-30 Alcon Lab Inc Sistema conservante para composicoes farmaceuticas topicamente administraveis contendo um sabao de acido gordo/amino acido
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
US6174914B1 (en) * 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
TR200200724T2 (tr) 1999-09-21 2002-06-21 Alcon Laboratories, Inc. Cilde sürülebilen farmasötik bileşimlerin antimikrobik etkisinin arttırılması için yağlı asit/amino asit sabunlarının kullanımı
CN1376066A (zh) 1999-11-18 2002-10-23 爱尔康公司 H1拮抗剂和安全类固醇的治疗眼病的用途
ATE291913T1 (de) * 2000-01-25 2005-04-15 Alcon Inc Antiallergische ophthalmische zubereitungen, geeignet zur anwendung mit kontaktlinsen
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
JP2006508138A (ja) 2002-11-12 2006-03-09 アルコン，インコーポレイテッド アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用

Also Published As

Publication number Publication date
ES2238574T3 (es) 2005-09-01
ATE295149T1 (de) 2005-05-15
JP2012107046A (ja) 2012-06-07
ZA200308771B (en) 2005-01-26
BRPI0210707B8 (pt) 2021-05-25
JP2009114213A (ja) 2009-05-28
US20030055102A1 (en) 2003-03-20
PL205565B1 (pl) 2010-05-31
MXPA03011947A (es) 2004-03-26
JP2004536096A (ja) 2004-12-02
JP5328947B2 (ja) 2013-10-30
BRPI0210707B1 (pt) 2015-08-04
US6995186B2 (en) 2006-02-07
EP1399127B1 (en) 2005-05-11
AU2002310461B2 (en) 2006-05-18
PL367780A1 (en) 2005-03-07
CA2447924A1 (en) 2003-01-09
GC0000397A (en) 2007-03-31
KR20040025919A (ko) 2004-03-26
JP4827374B2 (ja) 2011-11-30
US20050158387A1 (en) 2005-07-21
WO2003002093A1 (en) 2003-01-09
US7402609B2 (en) 2008-07-22
KR100884711B1 (ko) 2009-02-19
HK1059573A1 (en) 2004-07-09
CA2447924C (en) 2009-11-03
TWI231759B (en) 2005-05-01
EP1399127A1 (en) 2004-03-24
DE60204142D1 (de) 2005-06-16
JP2010150292A (ja) 2010-07-08
DK1399127T3 (da) 2005-06-13
CN1211125C (zh) 2005-07-20
AR034619A1 (es) 2004-03-03
DE60204142T2 (de) 2005-10-06
JP2013127005A (ja) 2013-06-27
PT1399127E (pt) 2005-07-29
CN1525849A (zh) 2004-09-01

Similar Documents

Publication Publication Date Title
BR0210707A (pt) Formulações de olopatadina para administração tópica
ES2052784T3 (es) Procedimiento para la produccion de una composicion terapeutica administrable localmente para una enfermedad inflamatoria.
BRPI0411916A (pt) imidazoquinolinas substituìdas por sulfonamida
ATE504579T1 (de) Antivirale mittel
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DOP2005000004A (es) "derivados sulfonamida para el tratamiento de enfermedades"
NO20044699L (no) Vaginalpleiesammensetning
ATE417610T1 (de) Zusammensetzung enthaltend 6-ä3-(1-adamantyl)-4- methoxyphenylü-2-naphthanoesäure zur behandlung dermatologischer erkrankungen
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
BR0307564A (pt) Derivados de nicotinamida úteis como inibidores de pde4
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
NO20040511L (no) Aminoisoxazolderivater som kinaseinhibitorer
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
DK1294353T3 (da) Anvendelse af en (R) -enantiomer af liponsyre i kosmetiske og dermatologiske sammensætninger
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
BR0307574A (pt) Derivados de nicotinamida úteis como inibidores de pde4
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
BRPI0721255B8 (pt) composições de olopatadina para administração nasal tópica
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
PT1289945E (pt) Derivados dissulfureto de anilina para o tratamento de doencas alergicas
BR0011503A (pt) Indução do fator de crescimento endotelial vascular (vdgf) pela proteìna de serina/treonina cinase akt
SV2002000626A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso ref. lea 34750-sv
ATE241640T1 (de) Fusidinsäure-derivate

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2727 DE 11-04-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.